Industry Overview

Drug discovery market was valued at $71.8 billion in 2025 and is projected to reach $178.06 billion by 2035, growing at a CAGR of 9.6% during the forecast Period (2026-2035). The market is expanding due to the increasing prevalence of chronic diseases and the demand for new therapies. Key drivers include advancements in technology like AI and machine learning, rising R&D investment, and the growing trend of personalized medicine. However, challenges such as high costs, stringent regulations, and the high failure rate in clinical trials continue to affect market growth.

Market Dynamics

Rising R&D Expenditure and Escalating Disease Burden

Global pharmaceutical and biotechnology companies are increasing their research and development spending to address the growing burden of chronic, infectious, and rare diseases. Higher incidence rates of cancer, cardiovascular disorders, neurological conditions, and emerging infections have created a strong need for new therapeutics, pushing organizations to expand and diversify their pipelines. Governments and private investors are also allocating larger budgets to biomedical research, strengthening academic–industry partnerships, and accelerating early-stage discovery efforts. This sustained rise in R&D investment forms a fundamental driver behind the continued expansion of the drug discovery market.

Technological Advancements in AI-driven Drug Design and Multi-omics

The integration of artificial intelligence, machine learning, and multi-omics technologies has transformed the landscape of drug discovery by reducing development timelines and improving the accuracy of target identification and lead optimization. AI-enabled in-silico modeling, predictive toxicology, structure-based drug design, and cloud-based computational platforms are dramatically enhancing efficiency and lowering attrition rates in early discovery stages. Additionally, innovations in high-throughput screening, CRISPR-based gene editing, next-generation sequencing, and proteomics have strengthened the understanding of disease pathways. These technological advancements collectively enable faster, data-driven discovery workflows, making them one of the strongest market growth drivers.

Increasing Outsourcing to CROs and Platform-based Discovery Models

Pharma and biotech companies are increasingly outsourcing drug discovery functions to contract research organizations (CROs), specialized discovery platforms, and integrated service providers. Outsourcing allows companies to access advanced technologies, skilled scientific expertise, and cost-efficient operations without expanding in-house infrastructure. CROs offer comprehensive services from target validation to ADME/Tox studies and preclinical evaluations, helping organizations accelerate development while optimizing resource usage. This shift toward externalized and platform-based discovery not only enhances operational flexibility but also creates opportunities for collaboration, strategic alliances, and shared-risk models, making outsourcing a major driver shaping the drug discovery market.

Market Segmentation

• Based on the type, the market is segmented into pharmacogenomics, high-throughput screening, genomics, bioinformatics, biochips, and nanotechnology.
• Based on the end user, the market is segmented into pharmaceutical companies, biopharmaceutical companies, biotech companies, and research institutes.

High Throughput Screening Segment to Grow at a Considerable Market Share

Among all the listed segments, High Throughput Screening (HTS) emerges as the largest and leading segment driving the growth of the Global Drug Discovery Market, owing to its central role in accelerating early-stage drug identification and reducing development timelines. HTS is widely adopted by pharmaceutical, biopharmaceutical, and biotechnology companies because it enables the rapid evaluation of thousands to millions of compounds against specific biological targets, significantly improving hit-to-lead efficiency. Its integration with automation, robotics, AI-driven assay analytics, and advanced compound libraries makes it indispensable for large-scale discovery programs.

The growing demand for faster, more accurate, and cost-effective discovery workflows, coupled with the increasing complexity of therapeutic areas such as oncology, neurology, and infectious diseases, continues to drive HTS adoption worldwide. As a result, HTS consistently accounts for the highest market share within the drug discovery technology landscape and remains the dominant, revenue-generating segment across end-user categories, making it the clear leader among all segments.

Biopharmaceutical Companies: A Key Segment in Market Growth

Among all the end-user segments in the global drug discovery market, pharmaceutical companies, biopharmaceutical companies, biotech companies, and research institutes, the biopharmaceutical companies segment stands out as the key driver of market growth due to its rapidly expanding focus on advanced therapies, strong investment capacity, and accelerated adoption of cutting-edge technologies. Biopharmaceutical firms are at the forefront of developing biologics, monoclonal antibodies, gene therapies, RNA-based drugs, and cell-based treatments, all of which require intensive, high-value discovery processes. Their pipelines are growing faster than those of traditional pharmaceutical companies, largely due to rising demand for targeted and personalized medicines, as well as increasing success rates associated with biologics. These companies also allocate a significantly higher share of revenue toward R&D, often exceeding 20%, allowing them to integrate AI-driven platforms, high-throughput screening systems, multi-omics data analytics, and advanced bioassays earlier and more aggressively than other end-users.

Additionally, biopharmaceutical companies rely heavily on collaboration with CROs, technology providers, and academic institutes to accelerate early-stage development, creating a strong ecosystem that fuels continuous innovation. The surge in chronic diseases, autoimmune disorders, rare diseases, and oncology indications has further boosted the demand for biologic therapeutics, making biopharma the fastest-growing segment in drug discovery. With the rise of mRNA-based platforms, personalized therapies, bispecific antibodies, and next-generation recombinant proteins, biopharmaceutical companies are positioned to maintain the largest growth momentum through the next decade, shaping the future landscape of global drug discovery.

Regional Outlook

The global drug discovery market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America  Region to Hold a Substantial Growth Rate

North America, particularly the US, dominates the global drug discovery market and holds the largest share by a significant margin. The US dominates the global drug discovery market with the largest share, driven by its highly advanced research infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and exceptional investment capacity in early-stage drug development. The country is home to a significant concentration of global innovators, including Pfizer, Merck, Johnson & Johnson, Bristol Myers Squibb, AbbVie, and hundreds of high-growth biotech firms that continuously expand their discovery pipelines. This ecosystem is further strengthened by world-class academic institutions, research universities, and government-funded scientific agencies such as the National Institutes of Health (NIH), which alone allocates billions of dollars annually to biomedical research and novel drug discovery initiatives.

The US also leads in technologies that are reshaping modern drug discovery, including artificial intelligence, machine learning platforms, multi-omics integration, CRISPR gene editing, high-throughput screening automation, and computational drug design, making it the global center for next-generation discovery innovation. In addition, the country’s strong intellectual property framework, mature venture capital landscape, and high rate of biotech start-up formation create a continuous pipeline of new therapeutic approaches and discovery platforms. Contract research organizations (CROs) and technology providers in the US also play a critical role, supporting pharmaceutical and biopharmaceutical companies worldwide with advanced screening, target validation, ADME/Tox studies, and early-stage development services. Collectively, these factors make the United States the undisputed leader in the global drug discovery landscape, consistently holding the highest market share and driving a substantial portion of global innovation, investment, and commercialization activity in the sector.

Market Players Outlook

The major companies operating in the global drug discovery market include AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Roche, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In November 2025, the FDA approved sevabertinib, the first cancer drug derived from Broad Institute research, marking a significant milestone in the collaboration between Broad Institute and Bayer. This oral medication targets non-small-cell lung cancer with specific HER2 mutations, providing treatment options for approximately 4,000 to 8,000 eligible patients annually in the US, particularly younger women who have never smoked. The drug's approval is supported by a Bayer clinical trial, which demonstrates an over 70 percent tumor reduction in the studied cohort.
• In November 2025, Biogen and Dayra Therapeutics announced a research collaboration aimed at discovering and developing oral macrocyclic peptides for various immunological conditions. These peptides are believed to provide biologic-like efficacy and safety in an oral format, which could potentially disrupt established antibody-based treatments. The collaboration seeks to broaden Biogen's immunology strategy and enhance its pipeline by incorporating this innovative modality. Biogen and Dayra will work together to identify, validate, and optimize these oral candidates targeting key immunological issues, with Biogen responsible for further development and potential commercialization.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global drug discovery market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.